What is the recommended treatment for Mobitz I (second‑degree atrioventricular block type I, Wenckebach) in an asymptomatic, hemodynamically stable adult?

Management of Mobitz I (Wenckebach) Heart Block

Asymptomatic Mobitz I Does Not Require Treatment in Most Cases

For asymptomatic, hemodynamically stable adults with Mobitz I second-degree AV block, observation without pacing is the standard approach, as this rhythm typically represents a benign AV-nodal level block with excellent prognosis. 1

---

Diagnostic Confirmation and Risk Stratification

• Confirm the diagnosis by identifying progressive PR-interval prolongation before a dropped QRS complex, followed by PR-interval reset—this group-beating pattern distinguishes Mobitz I from Mobitz II. 1

• Verify that the QRS complex is narrow (<120 ms), which confirms an AV-nodal level block rather than a dangerous infranodal (His-Purkinje) block. 1

• Rule out reversible causes systematically: acute myocardial infarction (especially inferior MI), medication effects (β-blockers, calcium-channel blockers, digoxin), electrolyte abnormalities, Lyme carditis, myocarditis, and thyroid dysfunction. 1

---

When Mobitz I Is Truly Benign

• Wenckebach is frequently asymptomatic and commonly observed in healthy athletes, during sleep, or with heightened vagal tone—these contexts indicate a benign, physiologic process. 1

• The prognosis of Wenckebach is benign in young, healthy individuals; progression to complete heart block is rare. 1

• In well-trained athletes, Wenckebach represents a vagally mediated adaptation and does not require intervention if it normalizes with exercise, atropine, or sympathetic stimulation. 2

---

When Observation or Intervention Is Required

Age and Comorbidity Considerations

• In patients ≥45 years of age with chronic Mobitz I, even asymptomatic individuals may have reduced five-year survival compared to age-matched controls, and pacemaker implantation should be considered. 3

• Patients with organic heart disease and Mobitz I have worse outcomes; pacing improves survival in this subgroup. 3

Symptomatic Patients

• Any patient with symptomatic bradycardia—syncope, presyncope, heart failure symptoms, chest pain, or dyspnea attributable to Mobitz I—requires permanent pacemaker implantation. 4

Exercise-Induced or Frequent Episodes

• If Wenckebach occurs during exertion or is frequent throughout the day despite normal autonomic tone, further evaluation with exercise stress testing or electrophysiologic study is warranted to exclude infranodal block. 5

• Rarely, Mobitz I can originate from infranodal (His-Purkinje) disease rather than the AV node; this variant predicts progression to complete heart block and mandates pacing. 5

---

Acute Medical Management (When Needed)

• Atropine 0.5–1 mg IV bolus, repeatable every 3–5 minutes up to a total of 3 mg, improves AV-nodal conduction in symptomatic Mobitz I. 4

• Atropine is effective only for AV-nodal level blocks; it will not help if the block is infranodal (wide-QRS escape). 4

• Temporary transcutaneous or transvenous pacing serves as a bridge in hemodynamically unstable patients until reversible causes are corrected or a permanent pacemaker is placed. 4

---

Indications for Permanent Pacemaker

• Permanent pacing is NOT routinely indicated for asymptomatic Mobitz I in young, healthy individuals or athletes. 1

• Permanent pacing IS indicated if:

  • Symptoms (syncope, heart failure, presyncope) are clearly attributable to the block. 4
  • The patient is ≥45 years old with chronic Mobitz I and organic heart disease. 3
  • Electrophysiologic study or exercise testing reveals infranodal origin of the block. 5
  • The block persists despite correction of reversible causes and the patient remains symptomatic. 4

---

Critical Pitfalls to Avoid

• Do not confuse Mobitz I with Mobitz II: Mobitz II shows constant PR intervals before dropped beats, occurs in the His-Purkinje system, and always requires pacing even if asymptomatic. 6, 7

• Do not label a 2:1 AV block as Mobitz I or II without observing consecutive beats to assess PR-interval behavior. 1

• Do not assume Mobitz I is benign in patients ≥45 years old or those with structural heart disease; these groups have worse outcomes without pacing. 3

• Do not implant a permanent pacemaker for asymptomatic vagally mediated Mobitz I in young, healthy individuals—this is classified as harmful. 4

• Do not delay evaluation if Mobitz I occurs during exercise or is frequent; this may indicate infranodal disease requiring pacing. 5

---

Practical Clinical Algorithm

1. Confirm Mobitz I on ECG: progressive PR prolongation → dropped QRS → PR reset, narrow QRS. 1

2. Assess symptoms: syncope, presyncope, heart failure, chest pain, dyspnea?

   • Yes → permanent pacemaker. 4
   • No → proceed to step 3.

3. Evaluate reversible causes: medications, electrolytes, MI, infection, thyroid.

   • Reversible cause found → treat and observe. 4
   • No reversible cause → proceed to step 4.

4. Assess patient age and comorbidities:

   • Age <45, no heart disease, athletic → observe; no pacing needed. 1, 2
   • Age ≥45 or organic heart disease → consider pacemaker even if asymptomatic. 3

5. If frequent or exercise-induced Mobitz I → perform exercise stress test or electrophysiologic study to exclude infranodal block. 5

   • Infranodal origin confirmed → permanent pacemaker. 5
   • AV-nodal origin confirmed → continue observation. 1